BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, February 15, 2026
See today's BioWorld
Home
» Amgen Spinout Relypsa Starts Business With $33M Series A
To read the full story,
subscribe
or
sign in
.
Amgen Spinout Relypsa Starts Business With $33M Series A
Oct. 31, 2007
By
Jennifer Boggs
If the story of newly established Relypsa Inc., a company created to develop nonabsorbed polymeric drugs for renal and cardiovascular diseases, sounds more than a little familiar, that's probably because it is. (BioWorld Today)
BioWorld